Vanda Pharmaceuticals has reported positive results from its safety and efficacy of tasimelteon (SET) Phase III study evaluating tasimelteon in the treatment of Non-24-Hour disorder, a rare circadian rhythm disorder.

Tasimelteon demonstrated the primary endpoint of entrainment of the melatonin (aMT6s) rhythm as compared to placebo in addition to demonstrating significant improvements across a number of sleep and wake parametres.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Vanda president and CEO Mihael Polymeropoulos said results indicate that tasimelteon is a strong circadian regulator capable of entraining the master body clock in patients with Non-24.

"We are particularly impressed and excited by the magnitude and robustness of the direct clinical benefits to patients," Polymeropoulos said.

"Tasimelteon demonstrated the primary endpoint of entrainment of the melatonin (aMT6s) rhythm as compared to placebo in addition to demonstrating significant improvements across a number of sleep and wake parametres."

"We believe that tasimelteon can be an effective and clinically meaningful treatment for patients suffering with this debilitating disorder."

See Also:

Considerable improvements over placebo in the Non-24 Clinical Response Scale (N24CRS) in addition to the Clinical Global Impression of Change (CGI-C), an overall global functioning scale, were demonstrated by tasimelteon in the study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

These results provide evidence of a direct and clinically meaningful benefit of the novel therapy in treating patients suffering from the rare circadian rhythm disorder.

Tasimelteon was safe and well-tolerated in the SET study. Top-line results from the second Phase III study (RESET) for tasimelteon in Non-24 are expected in the first quarter of 2013.

The company anticipates submitting a new drug application for tasimelteon to the US Food and Drug Administration in mid 2013.